abbreviations, 132. See also symbols
acamprosate, 50
acetylcholine-linked agents, 81
ACR16, 93
adrenergic receptors. See norepinephrine
affect meter, 23
aggression, and symptoms, 7, 28, 116, 124
agitation, and symptoms, 5–7, 11, 20, 24, 26
agonist spectrum, and atypical antipsychotics, 88, 90–1
alpha 2 autoreceptors, 36
alpha 2 delta ligands, 74–5. See also gabapentin; pregabalin
amisulpride, 89, 93–4
AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), 42, 82
amygdala, 28
amyotrophic lateral sclerosis (ALS), 72
anticholinergics, 77, 79
anticonvulsants, 51, 63, 81. See also carbamazepine; gabapentin; lamotrigine;
oxcarbazepine; pregabalin; riluzole; topiramate; valproate; zonisamide
antidepressants, and symptoms, 5–7, 28, 116
antihypertensives, 97, 99, 103, 105, 107
antipsychotics. See also atypical antipsychotics

cardiometabolic risk, 118–19
dopamine pathways, 39, 90
future compounds, 81–2
mechanisms of action as mood stabilizers, 85, 95
sedation, 123
weight gain, 119
antisocial personality disorder, 3
anxiety, 7, 10, 28, 50, 74. See also anxiety disorders
anxiety disorders, 3, 12, 116
apathy, and symptoms, 5, 21
apathy, and symptoms, 5, 21
appetite changes, and symptoms of depression, 5, 19, 22. See also eating habits;
weight gain or loss
aripiprazole, 85, 93–5, 106–107, 119, 126
arousal, and symptoms of mania, 24
asenapine, 108, 119, 126
attention-deficit/hyperactivity disorder (ADHD), 116
atypical antipsychotics. See also antipsychotics; aripiprazole; asenapine; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
agonist spectrum, 88
bipolar depression, 84
dopaminergic functioning, 38, 87–92
evidence-based bipolar combinations, 126
glutamate release, 43, 86
as mood stabilizers, 83
partial agonists, 88–94
sedation, 123–5

baseline measurements, and management of
mood stabilizers, 121
behavioral therapies, 129
benzodiazepines, 50, 112–14, 124
biapirunox, 93
biology, and basis of symptoms in bipolar
depression, 17. See also neurobiology
bipolar depression, 8, 10, 67, 84, 89,
114. See also depression
bipolar disorder. See also mania; mood
stabilizers; symptom-based treatment algo-

rithm; treatment; treatment-resistant bipolar
disorder
antidepressants in patients with, 128
atypical antipsychotics, 83
biological basis of symptoms, 17
bipolar spectrum, 15
common comorbidities, 12, 116
current best treatments for, 112
introduction to symptoms and spectrum of, 1
lithium and anticonvulsants as mood
stabilizers for, 51
maintenance pharmacy, 115
“mania-minded” versus “depression-
minded” treatment of, 111
mechanisms of action of antipsychotics in,
85
mood charts, 2
mood disorders and diagnosis of, 3
neurobiology and specific mechanisms of,
29
neurotransmission, 47
psychotherapy, 129
system-based approach to, 131
bipolar I and bipolar II disorders, symptoms
of, 11, 12
bipolar spectrum, 15
bipolar storm, 27, 47
blood pressure, 122
body mass index, 120–2
borderline personality disorder, 3, 116
140

Boston bipolar brew, 128
brain circuits, 17–28. See also neurobiol-
y; neurotransmission and neurotransmitters
calcium channel blockers, 48–9
calcium ion channels, 58, 62, 68, 72,
76. See also voltage-sensitive ion channels
(VSCCs and VSSCs)
California careful cocktail, 128
carbamazepine, 47–9, 62–3, 65–6, 77,
111, 123
carbonic anhydrase and carbonic anhy-
drase inhibitors, 49, 76, 77, 79
cardiometabolic risk, of mood stabilizers,
118–19, 122. See also side effects
cardiovascular disease, 120
cariprazine/RGH188, 93–4
circuits. See brain circuits
clozapine, 119
cognitive problems, in mania, 26. See also
concentration; executive dysfunction; racing
thoughts
combinations, of drugs, 126–8. See also
drug interactions
comorbidity, of bipolar disorder with other
diagnoses, 12, 116
COMT (catechol-O-methyl transferase), 39
congestion, and symptoms of depression,
19. See also distractibility
coping mechanisms, and psychotherapy,
129
CRF1 antagonists, 81
cyclothymia, symptoms of, 13
CYP 1A2 inhibitors and inducers, 73
CYP 3A4 inhibitors and inducers, 79, 97
CYP450 1A2 inhibitors and inducers, 103
CYP450 2D6 inhibitors, 97, 99, 107
CYP450 3A4 inhibitors and inducers, 97,
107
DA agonist, 99, 103, 105, 107. See also
dopamine partial agonist; D2 partial ago-
nist; D3 partial agonist
D2 antagonist, 90
D2 partial agonist, 89–90, 93
D3 partial agonist, 94
DAT (dopamine transporter), 39

d-cyclosporine, 82

delusions, and symptoms, 7, 28

depression. See also bipolar depression; double depression; major depressive disorder; unipolar depression

- brain circuits, 19, 28
- clinical actions of mood stabilizers, 111
- insomnia or hypersomnia, 26
- mood charts, 2, 9
- symptoms of, 5, 7, 19–23

diabetes, 120–1

diabetic ketoacidosis (DKA), 121

diagnosis. See also symptoms
diagnostic versus nondiagnostic symptoms, 28

- major depressive episode, 5
- manic episode, 6

misdiagnosis of bipolar disorder, 1, 3

Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), 5–6, 15
distractibility, and symptoms, 6–7, 11, 24, 26. See also concentration
dopamine (DA), and neurotransmission, 20, 23, 38–9, 87, 90. See also neurotransmitters and neurotransmission

dopamine agonists/antagonists, 39, 82. See also dopamine partial agonist; D2 partial agonist; D3 partial agonist
dopamine partial agonist (DPA), 112–15

dosing, of mood stabilizers

- aripiprazole, 107
- carbamazepine, 63
- lamotrigine, 69
- lithium, 55
- olanzapine, 103
- quetiapine, 97
- paliperidone, 101
- risulzole, 73
- risperidone, 99
- topiramate, 77
- valproate, 59
- ziprasidone, 105
- zonisamide, 79
double depression, 9
drug interactions

EAAT (excitatory amino acid transporter), 42

disthymia, 2, 9, 13

dyslipidemia, 121

dysthymia, 2

elevated mood, and mania, 6–7, 25
eslicarbazepine. See oxcarbazepine
euthymia, 2
evidence-based bipolar combos, of drugs, 126
excitation-secretion coupling, 46
executive dysfunction, and symptoms of depression, 5, 21. See also cognitive problems; concentration; information processing
extended-release (XR) formulation, of carbamazepine, 62

family members, roles in diagnosis and monitoring, 8, 117

fatigue, and symptoms of depression, 5, 19, 21
fibromyalgia, 74
fluoxetine, 114
friends, and diagnosis of unipolar or bipolar depression, 8
full agonists, 88–9

GABA (gamma-aminobutyric acid), 40, 48, 50
gabapentin, 48–50, 74, 111

maintenance therapy, for bipolar disorder, 115

major depressive disorder (MDD), 3, 5, 9, 14. See also depression

mania. See also bipolar disorder; hypomania;

psychotic mania

antidepressants, 128

anti-manic action at VSSCs, 47

antipsychotics, 95

asenapine, 108

atypical antipsychotics, 86–7, 89

brain circuits, 24–6, 28

carbamazepine, 66

clinical actions of mood stabilizers, 111

current best treatments for, 113

glutamate pathways, 41, 86

lithium, 56

mood chart, 2

partial agonists, 89

sedation as therapeutic tool, 124

symptoms of, 6–7, 24–6, 28, 50

valproate, 57

“metabolically friendly” mood stabilizers, 119

metabolic highway, and cardiovascular disease, 120

metabolic monitoring tool kit, 122

metabolism, of serotonin, 32

metabotropic glutamate receptor (mGluR), 42

mGluR agents, 82

migraines, and topiramate, 76

monitoring

of mood and mood disorders, 2, 117

of mood stabilizers, 121

monoamine(s), and symptoms of depression, 20

monoamine oxidase (MAO) enzymes, 32, 39

mood charts, 2, 8–14

mood disorders. See also anxiety disorders;

depression

comorbidity and treatment of bipolar disorder, 116

misdiagnosis of bipolar disorder, 3

monitoring of patients with, 117

hostility, and sedation as therapeutic tool, 124

hyperactivity, and mania, 26, 28

hyperinsulinemia, 120

hyperosmolar hyperglycemic state (HHS), 121

hypersexuality, and symptoms, 7, 28

hypomania, 2, 13

impulsivity, and symptoms, 7, 28, 116

information processing, 20–1, 38. See also executive dysfunction

insulin resistance, and psychopharmacologists, 122

inverse agonists, 89

irritability, and symptoms, 6–7, 11, 25

JZP-4, 81

kainate, 42

lamotrigine, 47–9, 59, 67–71, 111, 119, 127

levetiracetam, 48–9, 80, 111

lifestyle interventions, 121–2

lithium, 50–1, 54–6, 118–19, 123, 126–7

l-methylfolate (LMF), 112, 114

lithium, 50–1, 54–6, 111, 118–19, 123, 126–7

lifestyle interventions, 121–2

mood charts, 2, 8–14

mood disorders. See also anxiety disorders;

depression

comorbidity and treatment of bipolar disorder, 116

misdiagnosis of bipolar disorder, 3

monitoring of patients with, 117

hallucinations, and symptoms of mania, 7, 28

hostility, and sedation as therapeutic tool, 124

hyperactivity, and mania, 26, 28

hyperinsulinemia, 120

hyperosmolar hyperglycemic state (HHS), 121

hypersexuality, and symptoms, 7, 28

hypomania, 2, 13

impulsivity, and symptoms, 7, 28, 116

information processing, 20–1, 38. See also executive dysfunction

insulin resistance, and psychopharmacologists, 122

inverse agonists, 89

irritability, and symptoms, 6–7, 11, 25

JZP-4, 81

kainate, 42

lamotrigine, 47–9, 59, 67–71, 111, 119, 127

levetiracetam, 48–9, 80, 111

lifestyle interventions, 121–2

lithium, 50–1, 54–6, 118–19, 123, 126–7

l-methylfolate (LMF), 112, 114
mood charts and identification of, 9
as progressive, 14
mood lability, and bipolar depression, 10
mood stabilizers. See also anticonvulsants;
antipsychotics; dosing; drug interactions;
side effects
clinical actions, 111
combinations of, 126–7
dopaminergic pathways, 38
future antipsychotics, 81–2
glutamate release, 43
monitoring and managing, 121
neurotransmitters and mechanisms of
action, 48–9
symptom-based algorithm for, 28, 30, 50
voltage-sensitive calcium channels
(VSCCs), 45
voltage-sensitive sodium channels
(VSSCs), 44
motor retardation, and bipolar depression, 10

naltrexone, 50
negative affect, 23
NET (norepinephrine transporter), 36
net agonist, 88
neurobiology. See also brain circuits; neu-
rotransmission and neurotransmitters
introduction to specific mechanisms in
bipolar disorder, 29
symptom-based treatment algorithm, 30
understanding nature of illness, 17
neurokinin antagonists, 81
neuropathic pain, 74
neurotransmission and neurotransmitters.
See also brain circuits; dopamine; GABA;
glutamate; norepinephrine; serotonin;
voltage-sensitive ion channels (VSCCs and
VSSCs)
agonist spectrum, 88
atypical antipsychotics, 96
biology of mood stabilizers, 44–5
bipolar storm, 27, 47
symptom-based treatment algorithm, 30, 50
nicotine dependence, 116
NMDA (N-methyl-d-aspartate), 27, 42
noncompliance, and sedation, 125
norepinephrine (NE), and neurotransmission,
20, 23, 28, 35–7. See also neurotransmit-
ters and neurotransmission
norepinephrine and dopamine reuptake
inhibitors (NDRIs), 114
norquetiapine, 85, 96
“not otherwise specified” bipolar disorders
(NOS), 15
novelty seeking, and symptoms of mania/
bipolar spectrum, 7
olanzapine, 85, 95, 102–103, 114, 119,
125–6
oral contraceptives, 63, 69, 77
overactivity, and symptoms, 7
oxcarbazepine, 47–9, 64–6, 111
paliperidone, 85, 100–101, 119, 126
partial agonists, and atypical antipsychotics,
88–94. See also dopamine partial agonist;
D2 partial agonist; D3 partial agonist
peptide-linked agents, 81
personality disorders. See antisocial per-
sonality disorder; borderline personality
disorder
phenytoin, 77
pleasure, and symptoms of depression, 19, 21
positive affect, 23
positive allosteric modulators (PAMs), 82
postsynaptic norepinephrine receptors, 36
postsynaptic serotonin receptors, 34
posttest, and CME credit, 145–8
potassium ion channels, 62, 68, 72
practice-based bipolar combos, of drugs,
127
pramipexole, 93–4
prefrontal cortex (PFC), 28
pregabalin, 48–50, 74, 111
presynaptic alpha 2 norepinephrine recep-
tors, 37
presynaptic serotonin receptors, 33
progressive, bipolar disorder as, 14
psychopharmacologists, 122
psychosis and psychotic symptoms, 10, 38, 116, 124. See also schizophrenia
psychotherapy, 129
psychotic mania, and atypical antipsychotics, 86–7, 89, 124
quetiapine, 85, 95–7, 119, 125–6
racing thoughts, and symptoms of mania, 6–7, 24–5. See also cognitive problems
rapid cycling bipolar disorder, 13–14
recurrence, of manic episodes, 95
relapse, of bipolar disorder, 98
RGH188. See cariprazine
riluzole, 48–9, 71–3, 111
risk taking, and symptoms, 6–7, 11, 25
risperidone, 85, 95, 98–9, 119, 125–6
ropinirole, 93–4
sarcosine, 81
saredutant, 81
sarizotan, 93
schizophrenia, 3, 89, 108
second messenger activation, and partial agonists, 92
sedation, and antipsychotics, 123–5. See also side effects
selective serotonin reuptake inhibitors (SSRIs), 114
self-esteem, and symptoms, 11, 25
serotonin (5HT), and neurotransmission, 20, 31–4, 43. See also neurotransmitters and neurotransmission
serotonin agonist/antagonists, 82
serotonin-dopamine antagonist (SDA), 112–15
serotonin norepinephrine reuptake inhibitors (SNRIs), 114
serotonin transporter (SERT), 32
side effects
aripiprazole, 107
asenapine, 108
 carbamazepine, 63
 lamotrigine, 69
 lithium, 55
 olanzapine, 103
 paliperidone, 101
 psychopharmacologists and prevention of, 122
 quetiapine, 97
 riluzole, 73
 risperidone, 99
topiramate, 77
valproate, 59
ziprasidone, 104, 105
zonisamide, 79
sigma 1 agonists/antagonists, 82
signal propagation, role of VSCCs and VSSCs in regulation of, 46
signal transduction system, 34, 54, 58, 61, 91
silent antagonists, 89
sleep and sleep disturbances
bipolar depression, 10
gabapentin and pregabalin, 74
sedation as therapeutic tool, 124
symptoms of depression, 5, 19–20
symptoms of mania, 6–7, 24, 26
SLV313 and SLV314, 93
sodium ion channels, 68, 72, 76. See also voltage-sensitive ion channels (VSCCs and VSSCs)
somatodendritic autoreceptors, 33
SSR181507, 93
striatum, 28
sublingual formulation, of asenapine, 108
substance abuse and substance abuse disorders, 7, 28, 50, 116
suicidality and suicidal ideation, 5, 10, 19, 22, 56. See also side effects
 sulphiride, 89, 93–4
symbols, guides to, 51, 83. See also abbreviations
symptom(s). See also symptom-based treatment algorithm
bipolar depression, 10
bipolar I and bipolar II disorders, 11, 12
brain circuits, 17–18
cyclothymia, 13
depression, 5, 7, 19–23
diagnosis of unipolar versus bipolar depression, 8, 10
diagnostic versus nondiagnostic, 28
dysthymia, 13
mania, 6–7, 24–26, 28, 50
mood stabilizers and matching with, 50
symptom-based treatment algorithm, for bipolar disorder
brain circuits, 28
building of treatment plan, 109–10
identification of diagnostic and associated symptoms, 1, 4, 7
mood stabilizers, 28
neurotransmitters, 50
pharmacologic mechanisms, 53
synaptic vesicles, 49
systematic monitoring, 117
talkative pressured speech, and symptoms of mania, 6–7, 24–5
Tennessee mood shine, 128
thought and thinking. See cognitive problems; racing thoughts
thyroid hormones (T3/T4), 112, 114
topiramate, 47–50, 59, 76–7, 111
treatment. See also mood stabilizers; symptom-based treatment algorithm
bipolar depression, 114
building of plan for, 109–10
common comorbidities, 116
current best practices, 112–13
maintenance therapy, 115
monitoring and managing mood stabilizers, 121
psychopharmacologists, 122
psychotherapy, 129
sedation as therapeutic tool, 124
treatment portfolio, 110, 112
treatment-resistant bipolar disorder, 14
treatment-resistant unipolar depression, 89
triglycerides (TGs), 121
unipolar depression, 1, 8, 10, 14, 89. See also depression
valproate, 47–9, 57–61, 69, 77, 111, 118–19, 123, 126–7
varenicline, 50, 81
vesicular monoamine transporter 2 (VMAT2), 36, 39
v-Glu-T (vesicular transporter for glutamate), 42
violence, and sedation as therapeutic tool, 124
voltage-sensitive ion channels (VSCCs and VSSCs), 27, 44–7, 49–50, 60, 65, 70, 75. See also calcium ion channels; sodium ion channels
V1B antagonists, 81
weight gain or loss, as symptoms, 5, 7, 22, 119. See also appetite changes; body mass index; eating habits; side effects worthlessness, and symptoms of depression, 5, 19, 22
ziprasidone, 85, 95, 104–105, 119, 126
zonisamide, 47–50, 78–9, 111